11/18/20 4:05 PMNasdaq : KALAKala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 34,500 shares of Kala Pharmaceuticals common stock to four new employees. The stock options were granted on November 13, 2020. The grants were apprRHEA-AIvery positive
11/16/20 7:00 AMNasdaq : KALAKala Pharmaceuticals Provides Update on Launch Plans for EYSUVISTM for the Treatment of Dry Eye DiseaseKala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today provided an update on its plans to launch EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. "We continue to make significant progress on our plans to launch EYSUVIS and establRHEA-AIneutral
11/11/20 8:00 AMNasdaq : KALAKala Pharmaceuticals to Present at the Jefferies 2020 Virtual London Healthcare ConferenceKala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies 2020 Virtual London Healthcare Conference. Mark Iwicki, Chairman and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to participate in a fireside chat on Tuesday, November 17, 2020 at 2:05 p.m. GMT (9:05 a.m. ET). ToRHEA-AIneutral
10/29/20 8:00 AMNasdaq : KALAKala Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference CallKala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report third quarter 2020 financial results on Thursday, November 5, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET. The dial-in numbers to access the conference caRHEA-AIneutral
10/27/20 7:00 AMNasdaq : KALAKala Pharmaceuticals Announces FDA Approval of EYSUVIS(TM) for the Short-Term Treatment of the Signs and Symptoms of Dry Eye DiseaseKala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that the U.S. Food and Drug Administration (FDA) has approved EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. "The FDA approval of EYSUVIS as the first prescriptionRHEA-AIneutral
10/19/20 4:05 PMNasdaq : KALAKala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 42,000 shares of Kala Pharmaceuticals common stock to four new employees. The stock options were granted on October 15, 2020. The grants were approRHEA-AIvery positive
